U.S. regulators approved expanded use of Roche’s drug Hemlibra to include almost all patients with hemophilia A.
Biotech deal activity exploded with French drugmaker Sanofi and U.S.-based Celgene spending a combined total of more than $20 billion to add new products to their medicine cabinets.
